GlassScriptPhysician profile
Timothy E Kubal
NPI 1982808689
$49,417.15
in general payments reported to CMS, 2019-2025
11 companies · $8,926 in 2025
The $8,926 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $1,681 · 2022: $5,726 · 2023: $15K · 2024: $18K · 2025: $8,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Travel and Lodging: $2,498 · Honoraria: $1,764 · Food and Beverage: $815 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,778.00 |
| Travel and Lodging | $2,497.59 |
| Honoraria | $1,764.00 |
| Food and Beverage | $815.00 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $21,107.56 | 2022-2024 | Empaveli, Empaveli |
| Genzyme Corporation | $16,022.17 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $5,877.96 | 2019-2025 | |
| Genentech USA, INC. | $2,080.00 | 2022 | |
| Blueprint Medicines Corporation | $1,898.00 | 2023-2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $1,500.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $675.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $108.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $72.34 | 2021 | |
| Sobi, INC | $70.20 | 2022 | |
| Rigel Pharmaceuticals, INC. | $5.42 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Kubal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.